Solventum Corporation (SOLV) Operating Cash Flow CAGR:-80.44%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Solventum Corporation's Operating Cash Flow CAGR averages -56.37% over 3 years and -28.87% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Solventum Corporation generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
SOLV Operating Cash Flow CAGR Chart
Solventum Corporation (SOLV)
SOLV Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 12 quarters.
SOLV Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.19B | $369.00M | $-816.00M | -68.86% | -68.86% |
| 2024 | $1.92B | $1.19B | $-730.00M | -38.12% | -38.12% |
| 2023 | $1.68B | $1.92B | +$236.00M | +14.06% | +14.06% |
| 2022 | $2.20B | $1.68B | $-523.00M | -23.75% | -23.75% |
| 2021 | $2.03B | $2.20B | +$176.00M | +8.69% | +8.69% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | -$189.00M | — | — |
| Q4 2025 | $95.00M | +25.0% | -56.6% |
| Q3 2025 | $76.00M | -55.0% | -55.0% |
| Q2 2025 | $169.00M | — | -52.4% |
| Q1 2025 | $29.00M | -86.8% | -93.4% |
| Q4 2024 | $219.00M | +29.6% | -60.0% |
| Q3 2024 | $169.00M | -52.4% | -65.7% |
| Q2 2024 | $355.00M | -19.7% | -3.0% |
| Q1 2024 | $442.00M | -19.2% | -13.2% |
| Q4 2023 | $547.00M | +11.0% | +22.6% |
| Q3 2023 | $493.00M | +34.7% | -0.6% |
| Q2 2023 | $366.00M | -28.1% | -0.7% |
| Q1 2023 | $509.00M | +14.1% | +38.1% |
| Q4 2022 | $446.00M | -10.1% | — |
| Q3 2022 | $496.00M | +34.6% | — |
| Q2 2022 | $368.50M | +0.0% | — |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Bryan C. Hanson